HEMERA RECEIVES THE SEAL OF EXCELLENCE, THE EUROPEAN RECOGNITION FOR OUTSTANDING INNOVATION

Hemera’s REMaST project for the treatment of spinal cord injuries has been awarded the prestigious Seal of Excellence by the European Commission under the EIC Accelerator program, one of the most competitive instruments supporting technological innovation in Europe.
This recognition is reserved for projects that, although not funded due to budget limitations, have been evaluated as highly innovative, scientifically excellent, and with strong potential impact.

Hemera successfully passed all selection stages, reaching the final interview in Brussels, ranking among only 7 Italian companies to achieve this result out of hundreds of applications across Europe.

This milestone confirms the value of our technology and the strength of our vision to revolutionize the treatment of spinal cord injuries.

EUROPEAN PATENT GRANTED: A DECISIVE STEP IN PROTECTING HEMERA’S TECHNOLOGY

The European Patent Office has officially granted Hemera the European patent for the method underlying the REMaST technology, confirming the validity and originality of our scientific discovery. This milestone represents a crucial advancement in the protection of our intellectual property, which is essential to ensure the continuity and robustness of our therapeutic platform’s development. The patent grants exclusive rights over the core REMaST technology in major European countries, enhancing the company’s competitiveness on an international scale. Beyond safeguarding our scientific results, the patent also serves as a strategic asset to attract investments, establish new partnerships, and accelerate the path toward the commercialization of our therapy.

HEMERA’S SCIENTIFIC RESEARCH EARNS HIGH-LEVEL RECOGNITION

The research conducted by Hemera’s founding scientists has received significant recognition from the international scientific community, confirming its originality and innovative impact.

The study “Tumor-associated macrophages enhance tumor innervation and spinal cord repair”, published on a public repository, underwent public review by Nature Reviews Immunology, which described the data as pioneering and scientifically impactful.

The journal Cytotherapy, the official publication of the International Society for Cell & Gene Therapy, also highlighted Hemera as one of the most promising emerging players on the global stage.

These acknowledgments further strengthen Hemera’s position as an international scientific leader in the field of regenerative medicine.

HEMERA HONORED AMONG ITALY’S LEADING INNOVATORS WITH THE “AMERICA INNOVATION AWARD” IN ROME

On April 7, Hemera received the prestigious America Innovation Award, granted by the Italy – USA Foundation and presented at the Italian Chamber of Deputies in Rome. This international recognition is awarded annually to around 300 Italian startups and SMEs that stand out for their ability to innovate and compete in global markets, addressing some of the world’s most pressing challenges.

The America Innovation Award serves as a globally recognized certification of excellence and quality—an important signal for international investors and partners.

For Hemera, this award highlights the strength of our scientific vision and the revolutionary impact of the REMaST project in the field of regenerative medicine.

It is a tribute to the hard work, passion, and continuous commitment of our team in bringing the value of Made in Italy to the global stage, opening up new opportunities for collaboration and growth.